This in turn contributes to changes in positioning and signaling, leading to cell apoptosis.136,142 Therefore, TKI combined with FLT3 immunotherapy, which attenuates the level of glycosylation, may benefit AML patients. Here, FLT3 is linked to acute myeloid leukemia.